ESTRO 2024 - Abstract Book

S48

Invited Speaker

ESTRO 2024

Uncertainty Tolerances & Recommendations Establishing clinical tolerances for dosimetric procedures facilitated by DIR is intricate and currently lacks standardized guidelines. Accuracy requirements must align with the specific application, with uncertainties from DIRs necessitating quantitative translation to the dose level, which holds ultimate clinical relevance. Areas with high dose gradients are most sensitive to DIR errors. Presently, there is no uniform approach for reporting these uncertainties. Advancing DIR applications in clinical settings necessitates a heightened focus on accessible quantitative metrics and uncertainty assessment tools, especially within vendor-provided software. Additionally, developing standardized uncertainty quantification methods, tailored to diverse clinical applications and indications, followed by rigorous evaluation across multiple clinical settings, is imperative to establish robust tolerance levels.

3359

In silico simulations to support statistics, planning and analysis of clinical trials: The role of TCP and NTCP models

Christian Rønn Hansen

Odense University Hospital, Laboratory of Radiation Physics, Odense, Denmark. University of Southern Denmark, Institute of Clinical Research, Odense, Denmark. Aarhus University Hospital, Danish Center of Particle Therapy, Aarhus, Denmark

Abstract:

In today's dynamic landscape, computer simulations are indispensable tools across various industries, offering cost effective avenues to explore diverse scenarios and glean insights often inaccessible through real-world experimentation alone. Within radiotherapy, computer simulations, or what we term as treatment planning, have been ingrained since the introduction of computing technology. These simulations serve as the cornerstone of modern treatments, providing clinicians with patient-specific data regarding anticipated dosage distributions throughout the treatment. Moreover, with this dose simulation data, we can ascertain critical metrics such as Tumour Control Probabilities (TCP) and Normal Tissue Complication Probabilities (NTCP), thus empowering oncologists and patients alike with informed estimations regarding treatment outcomes and potential adverse effects. Beyond individual patient care, these simulations prove invaluable in cohort studies, offering a platform to assess the efficacy of novel equipment and treatment methodologies. Through meticulously designed treatment planning studies, we can systematically evaluate various techniques, enabling us to discern potential benefits. The forthcoming presentation will delve into the task of conducting comprehensive treatment planning studies. Furthermore, the talk will showcase compelling examples illustrating how TCP and NTCP models serve as indispensable tools in guiding the setup and analysis of clinical trials, thus paving the way for enhanced patient outcomes and advancements in oncological research.

3360

Inclusive pregnancy